Human Vγ9Vδ2 T cells show potent antitumor activity against zoledronate-sensitized OSCC cell lines.
Vγ9Vδ2 T cells exhibit potent antitumor effects against multiple types of tumors in preclinical models. In the present study, we examined whether human Vγ9Vδ2 T cells can be effective against oral squamous cell carcinoma (OSCC) cell lines in vitro because the interaction between OSCC and Vγ9Vδ2 T cells has not been explored previously. Eight OSCC cell lines were analyzed for their expression of ligands that potentially activate Vγ9Vδ2 T cells. Vγ9Vδ2 T cells were expanded in vitro from peripheral blood mononuclear cells (PBMCs) using zoledronate and IL-2. Expanded Vγ9Vδ2 T cells were tested for IFNγ production and cytotoxicity in response to zoledronate-treated OSCC cell lines. Flow cytometry was used to obtain and analyze data. All OSCC cell lines expressed CD277. The cell lines also expressed at least one type of NKG2D ligand. Zoledronate-treated OSCC cell lines induced IFNγ expression in Vγ9Vδ2 T cells. We thus found that Vγ9Vδ2 T cells efficiently kill zoledronate-sensitized OSCC cell lines. We found that zoledronate-treated OSCC cell lines are effectively killed by Vγ9Vδ2 T cells. Our results indicate that developing Vγ9Vδ2 T cell-based immunotherapy will be promising in treating patients with OSCC.